ANTENGENE CORP. DL-0001 Asset Resilience Ratio
ANTENGENE CORP. DL-0001 asset resilience ratio. ANTENGENE CORP. DL-0001 (722) has an Asset Resilience Ratio of 0.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 722 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ANTENGENE CORP. DL-0001 (2021–2025)
Asset resilience ratio of ANTENGENE CORP. DL-0001 from 2021 to 2025. This chart shows how ANTENGENE CORP. DL-0001's Asset Resilience Ratio has changed over time. Read ANTENGENE CORP. DL-0001 (722) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ANTENGENE CORP. DL-0001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of ANTENGENE CORP. DL-0001.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €107.00K | 0.01% |
| Total Liquid Assets | €107.00K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: ANTENGENE CORP. DL-0001 maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ANTENGENE CORP. DL-0001 Industry Peers by Asset Resilience Ratio
Compare ANTENGENE CORP. DL-0001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Genmab A/S
CO:GMAB |
Biotechnology | 23.50% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 4.91% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Viking Therapeutics Inc
NASDAQ:VKTX |
Biotechnology | 72.03% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
ANTENGENE CORP. DL-0001 Asset Resilience Ratio by Year (2021–2025)
ANTENGENE CORP. DL-0001 asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for ANTENGENE CORP. DL-0001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.01% | €107.00K ≈ $125.09K |
€1.26 Billion ≈ $1.47 Billion |
+0.00pp |
| 2024-12-31 | 0.01% | €106.00K ≈ $123.93K |
€1.34 Billion ≈ $1.57 Billion |
+0.00pp |
| 2023-12-31 | 0.01% | €105.00K ≈ $122.76K |
€1.62 Billion ≈ $1.89 Billion |
+0.00pp |
| 2022-12-31 | 0.00% | €103.00K ≈ $120.42K |
€2.14 Billion ≈ $2.50 Billion |
-3.74pp |
| 2021-12-31 | 3.74% | €95.74 Million ≈ $111.93 Million |
€2.56 Billion ≈ $2.99 Billion |
-- |
About ANTENGENE CORP. DL-0001
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse lar… Read more